News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
News UK biotechs T-Therapeutics and Alethio score big financings Two up-and-coming UK biotechs – T-Therapeutics and Alethio Therapeutics – have raised $133m and $90m, respectively, in impressive financing rounds.
News Dren Bio pockets $350m for rare blood cancer programme Dren Bio has closed a sizeable private financing round, raising $350m for pivotal trials of a possible first-in-class therapy for rare blood cancers.
News Under pressure, Novo lays out blockbuster launch plans Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
News AbbVie's cancer TCE etentamig hits the mark in myeloma AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.